Literature DB >> 23390904

[In Vitro Effect of Ankaferd Blood Stopper®, a Plant Extract Against Mycobacterium tuberculosis Isolates].

Aydın Deveci1, Ahmet Yılmaz Coban, Yeliz Tanrıverdi Çaycı, Ozlem Acicbe, Nuriye Taşdelen Fışgın, Alper Akgüneş, Düzgün Ozatlı, Meltem Uzun, Belma Durupınar.   

Abstract

Treatment of drug-resistant Mycobacterium tuberculosis infections requires combination of anti-tuberculosis drugs which have several toxic side effects. Thus there is a need for safer and effective new drugs. Ankaferd Blood Stopper® (ABS), which is a mixture of plant extracts prepared from Alpinia officinarum, Glycyrrhiza glabra, Thymus vulgaris, Urtica dioica and Vitis vinifera, has homeostatic and antibacterial effects. Standard solutions of ABS are already being used topically for post-traumatic and post-operative bleeding control in our country. This study was aimed to evaluate the in vitro activity of ABS against M.tuberculosis isolates. A total of 57 clinical isolates [17 multidrug resistant (MDR), 11 resistant to only isoniazid (INH), one resistant to INH and streptomycin (STR), two resistant only to STR, two resistant only to ETM, and 24 susceptible to all drugs] and three standard strains [H37Rv (susceptible to all drugs), ATCC 35822 (INH-resistant), ATCC 35820 (STR-resistant)] were included in the study. Agar dilution method was used to detect the MIC values of ABS. In the study, ABS MIC value was determined as 10.94 µg/ml for M.tuberculosis H37Rv strain which was susceptible to all anti-tuberculosis drugs, whereas it was determined as 21.88 µg/ml for INH-resistant ATCC 35822 and STR-resistant ATCC 35820 strains. The MIC values for 24 susceptible clinical isolates were as follows; 10.94 µg/ml (n= 17), 21.88 µg/ml (n= 6) and < 1.37 µg/ml (n= 1). When evaluating 17 MDR clinical isolates, MIC values were determined as 5.47 µg/ml (n= 1), 10.94 µg/ml (n= 5) and 21.88 µg/ml (n= 11). MIC values were ranging between < 1.37-21.88 µg/ml among 11 INH-resistant isolates. These isolates were susceptible to other first line anti-tuberculosis drugs. MIC value of one isolate resistant to both of INH and STR was determined as 21.88 µg/ml. MIC value of the two sole STR-resistant isolates was 21.88 µg/ml. MIC values of the two sole ETM-resistant isolates were determined as 21.88 µg/ml and 10.94 µg/ml. MIC50 and MIC90 values for the tested bacteria were 10.94 µg/ml and 21.88 µg/ml, respectively. It was concluded that 16 fold diluted concentration of the topically used ABS solution was found to be active against tuberculosis bacilli in vitro. Thus ABS might be used as a supportive agent together with anti-tuberculous drugs during debridement of multiple drug-resistant M.tuberculosis caused osteomyelitis and lymphadenitis lesions.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23390904     DOI: 10.5578/mb.4264

Source DB:  PubMed          Journal:  Mikrobiyol Bul        ISSN: 0374-9096            Impact factor:   0.622


  5 in total

1.  Qualitative/Chemical Analyses of Ankaferd Hemostat and Its Antioxidant Content in Synthetic Gastric Fluids.

Authors:  Ahmet Koluman; Nejat Akar; Umit Y Malkan; Ibrahim C Haznedaroglu
Journal:  Biomed Res Int       Date:  2016-01-26       Impact factor: 3.411

Review 2.  Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.

Authors:  Cem Simsek; Sebnem Selek; Meltem Koca; Ibrahim Celal Haznedaroglu
Journal:  SAGE Open Med       Date:  2017-07-27

3.  Antibacterial Activities of Ankaferd Hemostat (ABS) on Shiga Toxin-Producing Escherichia coli and Other Pathogens Significant in Foodborne Diseases.

Authors:  Ahmet Koluman; Nejat Akar; İbrahim C Haznedaroğlu
Journal:  Turk J Haematol       Date:  2015-08-06       Impact factor: 1.831

4.  Growth inhibitory activity of Ankaferd hemostat on primary melanoma cells and cell lines.

Authors:  Seyhan Turk; Umit Yavuz Malkan; Mehdi Ghasemi; Helin Hocaoglu; Duygu Mutlu; Gursel Gunes; Salih Aksu; Ibrahim Celalettin Haznedaroglu
Journal:  SAGE Open Med       Date:  2017-02-10

5.  Ankaferd hemostat (ABS) as a potential mucosal topical agent for the management of COVID-19 syndrome based on its PAR-1 inhibitory effect and oestrogen content.

Authors:  Fatma Beyazit; Yavuz Beyazit; Alpaslan Tanoglu; Ibrahim C Haznedaroglu
Journal:  Med Hypotheses       Date:  2020-07-31       Impact factor: 1.538

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.